NCT00790777View on ClinicalTrials.gov

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2007

Study Completion Date

May 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone ER

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00790777 - A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville | Biotech Hunter | Biotech Hunter